Product Description
MRZ-99030 (now GAL-101) is a proprietary compound designed to prevent the formation of all forms of toxic amyloid beta oligomers, by binding with high affinity to the misfolded amyloid beta monomers, but not to the normally folded version, before they can form toxic soluble oligomers.Ê These then rapidly conglomerate into amorphous, non-beta-sheet formations, which we call Òblobs.ÓÊ These ÒblobsÓ are innocuous and are thought to be cleared by the circulation. (Sourced from: https://www.galimedix.com/news-media/press-releases/detail/5/new-in-vitro-study-demonstrates-galimedix-therapeutics)
Mechanisms of Action: AB Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merz
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Geographic Atrophy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| eDREAM | P2 |
Not yet recruiting |
Geographic Atrophy |
2027-03-30 |